Free Trial

Precision BioSciences (DTIL) Competitors

Precision BioSciences logo
$4.29 -0.05 (-1.15%)
As of 03:48 PM Eastern

DTIL vs. EPRX, ENGN, TLSA, CTMX, OGI, GNFT, FDMT, IPHA, VTYX, and DERM

Should you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Eupraxia Pharmaceuticals (EPRX), enGene (ENGN), Tiziana Life Sciences (TLSA), CytomX Therapeutics (CTMX), Organigram Global (OGI), GENFIT (GNFT), 4D Molecular Therapeutics (FDMT), Innate Pharma (IPHA), Ventyx Biosciences (VTYX), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry.

Precision BioSciences vs. Its Competitors

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

In the previous week, Eupraxia Pharmaceuticals and Eupraxia Pharmaceuticals both had 2 articles in the media. Eupraxia Pharmaceuticals' average media sentiment score of 1.43 beat Precision BioSciences' score of 0.28 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Eupraxia Pharmaceuticals Positive
Precision BioSciences Neutral

Precision BioSciences has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eupraxia PharmaceuticalsN/AN/A-$25.50M-$0.76-7.29
Precision BioSciences$68.70M0.69$7.17M-$2.01-2.13

Eupraxia Pharmaceuticals has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500.

38.0% of Precision BioSciences shares are owned by institutional investors. 4.0% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Precision BioSciences' net margin of -42.99%. Precision BioSciences' return on equity of -69.26% beat Eupraxia Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Eupraxia PharmaceuticalsN/A -367.73% -112.23%
Precision BioSciences -42.99%-69.26%-29.30%

Eupraxia Pharmaceuticals presently has a consensus price target of $11.00, indicating a potential upside of 98.59%. Precision BioSciences has a consensus price target of $47.00, indicating a potential upside of 995.57%. Given Precision BioSciences' higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Eupraxia Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eupraxia Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Precision BioSciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Precision BioSciences beats Eupraxia Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Precision BioSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DTIL vs. The Competition

MetricPrecision BioSciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$47.58M$2.85B$5.44B$8.92B
Dividend YieldN/A2.44%5.22%4.00%
P/E Ratio-2.1320.4927.2520.05
Price / Sales0.69282.72426.50117.27
Price / CashN/A41.7026.2128.59
Price / Book0.627.407.925.57
Net Income$7.17M-$55.04M$3.17B$248.56M
7 Day Performance2.14%3.67%4.48%7.44%
1 Month Performance-21.86%0.33%2.80%8.43%
1 Year Performance-53.37%4.79%35.04%21.72%

Precision BioSciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DTIL
Precision BioSciences
4.5046 of 5 stars
$4.29
-1.2%
$47.00
+995.6%
-52.4%$47.58M$68.70M-2.13200
EPRX
Eupraxia Pharmaceuticals
2.4506 of 5 stars
$5.76
+8.7%
$11.00
+91.0%
+117.3%$190.57MN/A-7.5829Gap Up
High Trading Volume
ENGN
enGene
2.7791 of 5 stars
$3.64
-0.5%
$23.29
+539.7%
-57.6%$187.04MN/A-2.2131
TLSA
Tiziana Life Sciences
0.6732 of 5 stars
$1.58
-1.3%
N/A+85.5%$186.96MN/A0.008Positive News
CTMX
CytomX Therapeutics
3.8135 of 5 stars
$2.27
+0.9%
$5.33
+134.9%
+93.0%$181.40M$138.10M4.73170
OGI
Organigram Global
0.5367 of 5 stars
$1.35
flat
N/A-10.4%$180.82M$117.47M13.50860
GNFT
GENFIT
1.9781 of 5 stars
$3.73
+3.2%
$13.00
+249.0%
-8.2%$180.49M$67.00M0.00120Positive News
Gap Up
FDMT
4D Molecular Therapeutics
2.2618 of 5 stars
$3.71
-3.4%
$29.56
+696.6%
-80.6%$177.89M$40K-1.17120
IPHA
Innate Pharma
2.5259 of 5 stars
$1.82
-1.9%
$11.00
+506.1%
-8.5%$170.53M$21.77M0.00220Positive News
Gap Down
VTYX
Ventyx Biosciences
2.3707 of 5 stars
$2.14
-8.5%
$10.00
+367.3%
-3.5%$166.52MN/A-1.2230
DERM
Journey Medical
1.918 of 5 stars
$7.18
+0.6%
$9.50
+32.3%
+36.3%$166.33M$56.13M-18.4190Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:DTIL) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners